In another study, which analyzed 58 EGFR-mutant NSCLC patients developing small cell transformation after EGFR-TKI treatment, their median time since diagnosis of advanced NSCLC to SCLC transformation was 17.8 months; however, the EGFR-TKI prescribed in the study was not limited to the first- or second-generation, and 33% of these patients received the third-generation EGFR-TKI treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.